Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

ZEALAND PHARMA A/S - Group Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmarkIFRS Analyst: XBRLDenmarkIFRS

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   25.2% 25.1% 5.5% 7.3% 3.9% 6.1% 7.2% 6.6%   Credit score (0-100)   4 3 40 33 49 38 34 36   Credit rating   B B BBB BBB BBB BBB BBB BBB   Credit limit (mDKK)   0.0 0.0 0.0 0.0 0.0 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   41 192 109 104 343 63 63 63   Gross profit   40.9 192 97.6 104 324 54.8 0.0 0.0   EBITDA   -588 -626 -784 -837 -572 -1,272 0.0 0.0   EBIT   -588 -626 -784 -837 -572 -1,272 0.0 0.0   Pre-tax profit (PTP)   -576.7 -673.5 -758.9 -972.0 -708.9 -1,083.4 0.0 0.0   Net earnings   -571.5 -846.7 -1,018.1 -1,202.1 -703.7 -1,078.8 0.0 0.0   Pre-tax profit without non-rec. items   -577 -674 -759 -972 -709 -1,083 0.0 0.0     See the entire income statement 1.0 Balance sheet (mDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 86.5 50.5 47.0 46.5 0.0 0.0   Shareholders equity total   1,243 1,229 928 816 1,593 8,617 -6,157 -6,157   Interest-bearing liabilities   0.0 0.0 648 401 0.0 285 6,170 6,170   Balance sheet total (assets)   0.0 0.0 2,068 1,540 1,980 9,506 12.6 12.6   Net Debt   -1,081 -960 -481 -1,016 -449 -195 6,170 6,170     See the entire balance sheet 1.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   41 192 109 104 343 63 63 63   Net sales growth   8.8% 364.5% -43.5% -4.2% 229.6% -81.7% 0.0% 0.0%   Gross profit   40.9 192 97.6 104 324 54.8 0.0 0.0   Gross profit growth   18.2% 369.2% -49.2% 6.6% 211.2% -83.1% -100.0% 0.0%   Employees   173 297 346 0 0 235 0 0   Employee growth %   0.0% 71.7% 16.5% -100.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   0 0 2,068 1,540 1,980 9,506 13 13   Balance sheet change%   0.0% 0.0% 0.0% -25.5% 28.6% 380.1% -99.9% 0.0%   Added value   -587.9 -626.2 -784.3 -837.2 -572.2 -1,272.2 0.0 0.0   Added value %   -1,422.5% -326.2% -722.6% -805.1% -166.9% -2,029.3% 0.0% 0.0%   Investments   0 0 140 -90 9 -0 -46 0   Net sales trend   1.0 2.0 -1.0 -2.0 1.0 -1.0 0.0 0.0   EBIT trend   -1.0 -2.0 -3.0 -4.0 -5.0 -5.0 0.0 0.0   1.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   -1,422.5% -326.2% -722.6% -805.1% -166.9% -2,029.3% 0.0% 0.0%   EBIT %   -1,422.5% -326.2% -722.6% -805.1% -166.9% -2,029.3% 0.0% 0.0%   EBIT to gross profit (%)   -1,436.9% -326.2% -803.8% -805.1% -176.8% -2,320.8% 0.0% 0.0%   Net Earnings %   -1,382.8% -441.0% -938.0% -1,156.1% -205.3% -1,720.9% 0.0% 0.0%   Profit before depreciation and extraordinary items %   -1,382.8% -441.0% -938.0% -1,156.1% -205.3% -1,720.9% 0.0% 0.0%   Pre tax profit less extraordinaries %   -1,395.2% -350.8% -699.1% -934.8% -206.8% -1,728.2% 0.0% 0.0%   ROA %   0.0% 0.0% -35.9% -39.0% -29.4% -18.0% 0.0% 0.0%   ROI %   -24.3% -25.3% -25.0% -45.3% -33.7% -19.1% 0.0% 0.0%   ROE %   -24.2% -34.3% -47.2% -137.9% -58.4% -21.1% 0.0% 0.0%   1.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   50.0% 50.0% 44.9% 53.0% 80.4% 90.6% -99.8% -99.8%   Relative indebtedness %   -3,006.5% -640.3% 1,050.1% 696.1% 112.9% 1,417.8% 9,842.0% 9,842.0%   Relative net indebtedness %   -5,622.0% -1,140.4% 9.9% -667.3% -18.1% 651.7% 9,842.0% 9,842.0%   Net int. bear. debt to EBITDA, %   183.9% 153.3% 61.4% 121.4% 78.5% 15.3% 0.0% 0.0%   Gearing %   0.0% 0.0% 69.8% 49.2% 0.0% 3.3% -100.2% -100.2%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 4.9% 51.1% 95.1% 36.1% 0.0% 0.0%   1.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   -0.0 -0.0 4.8 6.7 6.2 21.1 0.0 0.0   Current Ratio   -0.0 -0.0 5.1 6.7 6.3 21.1 0.0 0.0   Cash and cash equivalent   1,081.1 960.2 1,129.1 1,417.8 449.3 480.3 0.0 0.0   1.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 516.0 405.8 104.1 1,126.9 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 1,586.1% 1,265.9% 519.2% 13,602.8% 0.0% 0.0%   Net working capital   1,242.7 1,229.3 1,387.3 1,120.9 1,495.2 8,124.2 -3,085.0 -3,085.0   Net working capital %   3,006.5% 640.3% 1,278.1% 1,077.9% 436.2% 12,959.2% -4,921.0% -4,921.0%   1.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 1 0 0 0 0 0 0   Added value / employee   -3 -2 -2 0 0 -5 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -3 -2 -2 0 0 -5 0 0   EBIT / employee   -3 -2 -2 0 0 -5 0 0   Net earnings / employee   -3 -3 -3 0 0 -5 0 0